Research
Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target
Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $10.58, according to analysts polled by FactSet.
$ACRS
$ACRS
3 stories mentioning ACRSUpdated 22d ago
Every FINWIRES story that references ACRS, newest first.
What are analysts saying about ACRS?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on ACRS?
Insider Trading
Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing
Braden Michael Leonard, 10% Owner, on April 27, 2026, sold 300,000 shares in Aclaris Therapeutics (ACRS) for $1,359,000. Following the Form 4 filing with the SEC, Leonard has control over a total of 13,950,000 common shares of the company, with 13,950,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1557746/000137360426000034/xslF345X05/form4.xml
$ACRS
Research
Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target
Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $8.94, according to analysts polled by FactSet.
$ACRS
